Literature DB >> 21924104

[Management of oral mucositis in patients with head and neck cancer receiving chemoradiotherapy and/or molecular targeted therapy].

Xin-xin Zhang1, Lin Ma, Jia-ling Wang, Wen-ming Wu, Lin-chun Feng, De-liang Huang.   

Abstract

OBJECTIVE: To investigate the prevalence and treatment of oral mucositis caused by concurrent chemoradiotherapy and/or molecular targeted therapy in the patients with advanced squamous cell carcinoma of the head and neck.
METHODS: A retrospective study of the incidence and treatment of oral mucositis was performed in 179 patients (155 male and 24 female;124 patients at stage III and 55 patients at stage IV) receiving concurrent chemotherapy and (or) molecular targeted therapy between November 2007 and November 2010. Grade I, II, III and IV oral mucositis occurred respectively in 49, 50, 67 and 13 patients. All the patients received oral mucositis prophylaxis. After the occurrence of oral mucositis, conventional treatment of mucositis combined with quinolone antibiotics were applied.
RESULTS: Of the patients, 99 patients with grade I or II and 4 patients with grade III oral mucositis were effectively managed by conventional treatment; 76 patients with grade III or IV oral mucositis were also significantly controled by conventional treatment plus antibiotics. After the treatments, all patients with oral mucositis were under control, with the decrease in the grade of oral mucositis, the reduction of oral pain and the improvement in ability to eat. None of them had radiation treatment breaks.
CONCLUSIONS: Combined modality therapy can effectively control chemoradiation-induced oral mucositis in patients with head and neck squamous cell carcinoma, grade I and II oral mucositis were cured by conventional treatment and quinolone antibiotics play a key role in the treatments for grade III and IV oral mucositis.

Entities:  

Mesh:

Year:  2011        PMID: 21924104

Source DB:  PubMed          Journal:  Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi        ISSN: 1673-0860


  5 in total

1.  SAMITAL® improves chemo/radiotherapy-induced oral mucositis in patients with head and neck cancer: results of a randomized, placebo-controlled, single-blind Phase II study.

Authors:  D Pawar; R S Neve; S Kalgane; A Riva; E Bombardelli; M Ronchi; G Petrangolini; P Morazzoni
Journal:  Support Care Cancer       Date:  2012-09-04       Impact factor: 3.603

2.  A Phase II Clinical Trial of Concurrent Helical Tomotherapy plus Cetuximab Followed by Adjuvant Chemotherapy with Cisplatin and Docetaxel for Locally Advanced Nasopharyngeal Carcinoma.

Authors:  Xinxin Zhang; Lei Du; Feifang Zhao; Qiuju Wang; Shiming Yang; Lin Ma
Journal:  Int J Biol Sci       Date:  2016-02-12       Impact factor: 6.580

3.  Efficacy of non-surgical larynx-preservation comprehensive treatment in advanced laryngeal carcinoma.

Authors:  Nan-Xiang Chen; Wen-Jun Fan; Lin Ma; Jia-Ling Wang; Wen-Ming Wu; Xin-Xin Zhang
Journal:  Chin Med J (Engl)       Date:  2020-03-05       Impact factor: 2.628

4.  Clinical outcomes of patients with nasopharyngeal carcinoma treated with antibiotics for radiation-induced mucositis: a retrospective study.

Authors:  JingJin Weng; Jiazhang Wei; Min Li; Jinlong Lu; Yangda Qin; Fei Liu; Weiming Xiong; Shenhong Qu
Journal:  J Int Med Res       Date:  2019-12-16       Impact factor: 1.671

5.  Multimodal Treatment With Orbital Organ Preservation in Adult Patients With Locally Advanced Small-Round-Cell Malignancy of the Nasal Cavity and Paranasal Sinus.

Authors:  Nanxiang Chen; Hu Yuan; Wenjun Fan; Lin Ma; Kun Liu; Lei Chen; Shiming Yang; Xinxin Zhang
Journal:  Front Oncol       Date:  2021-04-01       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.